Marketing gimmick so Muji can make a profit and folks can post to social media lol

"By design, the open-label study arm did not assign participants to receive a placebo, so STOMP will not draw conclusions about the efficacy of tecovirimat in participants with, or at elevated risk for, severe clade II mpox"....

#idsky